References
- Cheung AK, Sarnak MJ, Yan G, et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int. 2004;65(6):2380–2389
- Crea F, Liuzzo G. Pathogenesis of acute coronary syndromes. J Am Coll Cardiol. 2013;61(1):1–11
- Carter AM. Inflammation, thrombosis and acute coronary syndromes. Diab Vasc Dis Res. 2005;2(3):113–121
- Falk E, Nakano M, Bentzon JF, et al. Update on acute coronary syndromes: the pathologists' view. Eur Heart J. 2013;34(10):719–728
- Legein B, Temmerman L, Biessen EA, et al. Inflammation and immune system interactions in atherosclerosis. Cell Mol Life Sci. 2013;70(20):3847–3869
- Alard JE, Gaillard F, Daridon C, et al. TLR2 is one of the endothelial receptors for beta 2-glycoprotein I. J Immunol. 2010;185(3):1550–1557
- Blich M, Golan A, Arvatz G, et al. Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression. Arterioscler Thromb Vasc Biol. 2013;33(2):e56–e65
- Seimon TA, Nadolski MJ, Liao X, et al. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab. 2010;12(5):467–482
- Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by toll-like receptor 2. J Clin Invest. 2005;115(11):3149–3156
- Chen YY, Chen J, Hu JW, et al. Enhancement of lipopolysaccharide-induced toll-like receptor 2 expression and inflammatory cytokine secretion in HUVECs under high glucose conditions. Life Sci. 2013;92(10):582–588
- Pagano S, Satta N, Werling D, et al. Anti-apolipoprotein A-1 IgG in patients with myocardial infarction promotes inflammation through TLR2/CD14 complex. J Intern Med. 2012;272(4):344–357
- Fukushima R, Soejima H, Fukunaga T, et al. Expression levels of toll-like receptor genes in coronary atherosclerotic lesions of patients with acute coronary syndrome or stable angina pectoris. Circ J. 2009;73(8):1479–1484
- Pryshchep O, Ma-Krupa W, Younge BR, et al. Vessel-specific toll-like receptor profiles in human medium and large arteries. Circulation. 2008;118(12):1276–1284
- Monaco C, Gregan SM, Navin TJ, et al. Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation. 2009;120(24):2462–2469
- Mullick AE, Soldau K, Kiosses WB, et al. Increased endothelial expression of toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events. J Exp Med. 2008;205(2):373–383
- Gluba A, Banach M, Hannam S, et al. The role of toll-like receptors in renal diseases. Nat Rev Nephrol. 2010;6(4):224–235
- Hasu M, Thabet M, Tam N, et al. Specific loss of toll-like receptor 2 on bone marrow derived cells decreases atherosclerosis in LDL receptor null mice. Can J Physiol Pharmacol. 2011;89(10):737–742
- Kuwahata S, Fujita S, Orihara K, et al. High expression level of toll-like receptor 2 on monocytes is an important risk factor for arteriosclerotic disease. Atherosclerosis. 2010;209(1):248–254
- Cole JE, Georgiou E, Monaco C. The expression and functions of toll-like receptors in atherosclerosis. Mediators Inflamm. 2010;2010:393946
- Versteeg D, Hoefer IE, Schoneveld AH, et al. Monocyte toll-like receptor 2 and 4 responses and expression following percutaneous coronary intervention: association with lesion stenosis and fractional flow reserve. Heart. 2008;94(6):770–776
- Moghimpour Bijani F, Vallejo JG, Rezaei N. Toll-like receptor signaling pathways in cardiovascular diseases: challenges and opportunities. Int Rev Immunol. 2012;31(5):379–395
- Chao W, Shen Y, Zhu X, et al. Lipopolysaccharide improves cardiomyocyte survival and function after serum deprivation. J Biol Chem. 2005;280(23):21997–22005
- Arslan F, Smeets MB, O'Neill LA, et al. Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation. 2010;121(1):80–90